A new and highly capitalized market player has boldly declared its debut as a developer of allogeneic, off-the-shelf iPCS-derived cell therapeutics. GC Therapeutics (GCTx) has officially launched, bringing with it a revolutionary approach to cell therapy that aims to overcome current challenges in scalability, efficiency, and cost-effectiveness that have traditionally hindered the development of iPSC-derived therapies. With the debut of its innovative TFome™ platform, GCTx is positioned to scale the full potential of induced pluripotent stem cell (iPSC)-based therapies.
The TFome™ platform utilizes cutting-edge transcription factor (TF) programming to rapidly differentiate iPSCs into functional cell types in a single-step process, creating what the company refers to as “SuperCells™” — that is, cells with optimized potency and therapeutic efficiency. What makes the the TFome platform exciting and revolutionary is that can produce off-the-shelf cell therapies significantly faster than traditional cell differentiation methods—up to 100X more rapidly—while enhancing potency, efficiency, quality, and cost-effectiveness of its cellular end-products.
This breakthrough was developed from research originating in the lab of George Church, Ph.D., professor of genetics at Harvard Medical School. GCTx’s innovation is supported by Harvard’s Blavatnik Biomedical Accelerator and backed by strong intellectual property protections. The company has also assembled a star-studded leadership team.
The company is well capitalized, having secured $65 million in Series A funding, with Cormorant Asset Management leading the round. Additional investors included Mubadala Capital, Andreessen Horowitz (a16z) Bio + Health, Medical Excellence Capital, Cercano Management, and Pear VC, bringing the company’s total funding to an impressive $75 million.
GCTx was co-founded by Parastoo Khoshakhlagh, Ph.D., who serves as the CEO, Alex Ng, Ph.D., the CSO, Cory Smith, Ph.D., the scientific co-founder and head of discovery platforms, and George Church, Ph.D., a professor of genetics at Harvard Medical School and core faculty member at the Wyss Institute for Biologically Inspired Engineering.
The company’s board of directors and advisers include: Ray Kelleher, M.D., Ph.D., managing director at Cormorant Asset Management; Vineeta Agarwala, M.D., Ph.D., general partner at a16z Bio + Health; Alaa Halawa, MBA, executive director and head of U.S. ventures at Mubadala Capital; John Maraganore, Ph.D., CEO of JMM Innovations and founding CEO of Alnylam Pharmaceuticals; and Steve Paul, M.D., former CEO of Karuna Therapeutics and co-founder of Rapport Therapeutics and Seaport Therapeutics.
A Single-Step Process for iPSC Cell Fate Differentiation
The TFome platform represents a significant advancement in cell therapy technology. By incorporating the full collection of human transcription factors, GCTx’s system can guide iPSC cell differentiation in a single, seamless step. This process achieves over 90% efficiency within just four days, without the need for environmental optimization typically required for other methods. According to GCTx co-founder and CEO, Dr. Parastoo Khoshakhlagh, this innovation promises to make cell therapy more accessible and cost-effective, potentially accelerating the development of treatments for a variety of diseases, starting with gastrointestinal, neurological, and immunological conditions.
GCTx’s ability to scale its platform offers an advantage over existing cell therapy approaches. The streamlined process of TF-based cell programming allows for the rapid production of high-quality, off-the-shelf cell therapies, drastically reducing timelines from years to weeks or months. The company is also pursuing multiple cell products using a similar manufacturing process, thus expanding its therapeutic potential across different disease areas.
GCTx’s ultimate goal is to make transformative, iPSC-based therapies widely accessible, significantly reducing healthcare costs and improving patient outcomes. With a highly experienced team and a robust pipeline of potential therapies, GCTx is positioned to lead the next generation of cell therapy innovation.
To learn more, view the GCTx launch announcement here.
